N
Neuraltus Pharmaceuticals
Neuraltus Pharmaceuticals, Inc.
About Neuraltus Pharmaceuticals
Neuraltus Pharmaceuticals, Inc. operated as a privately-held biopharmaceutical firm with a focus on creating treatments for neurodegenerative diseases. The company was founded in 2004 and established its headquarters in Palo Alto, California. Roland E. Dolle, Ph.D., served as a co-founder and held the position of Vice President of Chemistry.
The company's primary efforts were directed towards developing and commercializing therapeutics for conditions with significant unmet medical needs, particularly amyotrophic lateral sclerosis (ALS). Neuraltus' business model centered on advancing its drug candidates through the rigorous clinical trial process, a capital-intensive and lengthy endeavor typical of the biopharmaceutical industry. The ultimate goal was to gain regulatory approval and bring a new treatment to market for patients suffering from neurodegenerative disorders. The company engaged with global ALS specialists and patient advocacy groups to guide its clinical development strategy.
Its lead drug candidate was NP001, a small molecule regulator of macrophage activation. In individuals with ALS, inflammation in the central nervous system involves activated macrophages that can be toxic to neurons. NP001 was designed to convert these pro-inflammatory macrophages back to their normal, non-inflammatory state, thereby aiming to slow the progression of the disease and reduce neuronal damage. Despite promising initial studies, NP001 unfortunately failed to meet its primary and secondary endpoints in a Phase 2 clinical trial involving 138 ALS patients. Following the announcement of these trial results in early 2018, Neuraltus Pharmaceuticals ultimately ceased operations.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2004
- Headquarters
- Palo Alto, United States
- Employees
- 4
- Open positions
- None listed
- Dealroom signal
- 56.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Client focus
- B2C
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | May 2016 | $15M | $60M | VantagePoint Capital Partners · Latterell Venture Partners | — |
| EARLY VCOther financing | Apr 2012 | $1.5M | $6M | Adams Street Partners · Latterell Venture Partners | — |
Growth signals
Latest recorded traffic for Neuraltus Pharmaceuticals is 220 monthly website visits. Neuraltus Pharmaceuticals's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Neuraltus Pharmaceuticals in the Palo Alto ecosystem
The Neuraltus Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Adams Street Partners
Latterell Venture Partners
VantagePoint Capital Partners
Other known investors2 additional known investors
Stanford University
University of California, San Francisco
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Neuraltus Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Neuraltus Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








